Strides Pharma Science Limited share price
NSE: STAR · ISIN INE939A01011
Key numbers
- Market cap
- ₹ 10,922 Cr
- Current price
- ₹ 1,184.90
- 52-week high / low
- ₹ 1,261 / 769
- Stock P/E
- 17.8
- Book value
- ₹ 337.2
- Dividend yield
- 0.42%
- ROCE
- 17.6%
- ROE
- 19.7%
- Debt to equity
- 0.57
- Sales growth (3 yrs)
- 8.7%
- Profit growth (3 yrs)
- -
- 1-year return
- 40.1%
About Strides Pharma Science Limited
Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,190 | 1,120 | 1,195 | 1,323 | 1,265 |
| Operating profit | 218 | 218 | 236 | 240 | 230 |
| Net profit | 82 | 100 | 202 | 127 | 157 |
| EPS (₹) | 8.92 | 10.81 | 21.93 | 13.77 | 17.02 |
Concall summary (2026-08-03)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- For Q1 FY27, we delivered 13% year on year growth in Strides Pharma Science Limited July 31, 2026 topline, supported by broad -based contributions across our business.
- Despite additional operating and freight cost of ₹131m arising from ongoing geopolitical situations, our EBITDA margins were maintained at 18.2%, broadly in l ine with the exit levels of Q4 FY26.
Growth & demand
- Our Ex -US markets continued to demonstrate strong momentum, delivering 17% year-on-year growth.
- Coming to the US business, revenue for the quarter stood at ₹6,282 million or $68 million, reflecting a stable performance despite increased competition in certain products launched over the last few quarters.
Margins & costs
- Our objective continues to be to maintain gross margins within the 58% to 60% range, and deliver superior EBITDA margins driving operating leverage that translates into sustained EPS and P AT growth over the medium term.
- Gross margin expanded 60 basis points year -on-year to 60.9%, driven by favourable business mix within Ex-US markets, and drove 14% growth in absolute gross margin to ₹770.2 crore.
Capex & expansion
- We now have multiple projects progressing across these technology platforms and continue to invest in building a differentiated pipeline that can support sustainable growth over the medium term.
- At the same time, Africa delivered another strong quarter, led by the continued expansion of our Brands business.
Balance sheet & cash
- After funding this working capital investment, we generated operating cash flow of ₹108.7 crore for the quarter, an EBITDA-to-cash conversion of 47%. we reduced net debt by ₹11.9 crore during the quarter, bringing closing net debt to ₹1,424.6 crore and net debt -to-EBITDA down to 1.52x, from 1.55x at the end of FY26.
- From an overall perspective, the current net debt is about INR14.2 billion, like INR1,420 crores.
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.